Essa Pharma Inc. is facing significant financial challenges amidst market volatility, but the company remains committed to developing innovative treatments for prostate cancer.

Essa Pharma Inc.’s stock has experienced significant volatility, with a 52-week high of $7.88 and a 52-week low of $1.4, due to the company’s struggles with profitability and the high-risk nature of biotech investments.

ESSA Pharma Inc. has agreed to be acquired by XenoTherapeutics in an all-cash transaction, providing shareholders with immediate financial benefits and potential future gains through contingent value rights.

Essa Pharma Inc. continues to focus on developing small molecule drugs to treat prostate cancer, despite recent financial fluctuations, and remains committed to its research initiatives in oncology.